Selumetinib in adults with NF1 and inoperable plexiform neurofibroma

The MEK inhibitor selumetinib induces objective responses and provides clinical benefit in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs). To evaluate whether similar outcomes were possible in adult patients, in whom PN growth is generally slower than in pediatric patients, an open-label phase 2 study of selumetinib in adults with NF1 PNs was conducted. Correlative analysis included extraction of RNA followed by sequencing. Samples include paired specimens collected before and on treatment. Overall design: RNA-seq was performed for gene expression profiling analysis in tumors collected before and on treatment with the MEK inhibitor Selumetinib.